Claudes syndrome is a form of brainstem stroke syndrome characterized by the presence of an ipsilateral oculomotor nerve palsy, contralateral hemiparesis, contralateral ataxia, and contralateral hemiplegia of the lower face, tongue, and shoulder. Claudes syndrome affects oculomotor nerve, red nucleus and brachium conjunctivum. Cause
Claudes syndrome is caused by midbrain infarction as a result of occlusion of a branch of the posterior cerebral artery. This lesion is usually a unilateral infarction of the red nucleus and cerebellar peduncle, affecting several structures in the midbrain including:

It is very similar to Benedikts syndrome. Other causes
It has been reported that posterior cerebral artery stenosis can also precipitate Claudes syndrome. Diagnosis
History
It carries the name of Henri Charles Jules Claude, a French psychiatrist and neurologist, who described the condition in 1912. See also
Wallenbergs syndrome
Moritz Benedikt

References


== External links ==
Marketing
Methocarbamol without other ingredients is sold under the brand name Robaxin in the U.K., U.S., Canada and South Africa; it is marketed as Lumirelax in France, Ortoton in Germany and many other names worldwide. In combination with other active ingredients it is sold under other names: with acetaminophen (paracetamol), under trade names Robaxacet and Tylenol Body Pain Night; with ibuprofen as Robax Platinum; with acetylsalicylic acid as Robaxisal in the U.S. and Canada. However, in Spain the tradename Robaxisal is used for the paracetamol combination instead of Robaxacet. These combinations are also available from independent manufacturers under generic names. Research
Although opioids are a typically first line in treatment of severe pain, several trials suggest that methocarbamol may improve recovery and decrease hospital length of stay in those with muscles spasms associated with rib fractures. However, methocarbamol was less useful in the treatment of acute traumatic pain in general.Long-term studies evaluating the risk of development of cancer in using methocarbamol have not been performed. There are currently no studies evaluating the effect of methocarbamol on mutagenesis or fertility.The safety and efficacy of methocarbamol has not been established in pediatric individuals below the age of 16 except in tetanus. References
External links
"Methocarbamol". Drug Information Portal. U.S. National Library of Medicine.